cafepharma

We’re running a short, anonymous survey to better understand how those in the industry are using AI today. Results will be shared at a high level with the community. Please let us know your thoughts here: forms.gle/8xPdatew4hDh8Kxk9

Tue news: Pfizer hikes full-year outlook as newer products grow. Abbott’s Amulet 360 demonstrates strong one-year outcomes in AFib patients. Abbott’s Amulet 360 demonstrates strong one-year outcomes in AFib. Bayer hits "turning point" in recovery plan. —bit.ly/3JeBlY5

Mon news: U.S. bioscience jobs up 7% from 2021 to 2025. Teva ends trial of one of its original line-up of innovative meds over futility. How well is J&J’s incubator model working? Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict. —bit.ly/3JeBlY5

Fri news: AbbVie lifts profit forecast as immunology drugs continue to fuel growth. Keytruda biosims are coming. Sanofi eyeing pipeline deals ahead of Dupixent patent loss. AZ is launching a $1.5 billion cost-savings program to fund its drug pipeline. —bit.ly/3JeBlY5

Thurs news: Merck tops quarterly estimates with strong performance from new Keytruda form. Lilly hikes sales outlook. Abbott grows cardiac portfolio with Amplatzer approval for valve leaks.Biopharma cuts at manufacturing plants expected to affect 4,000+. —bit.ly/3JeBlY5

Wed news: Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss. Big Pharma ready to strike, with J&J most likely to buy. Biogen notches 3rd straight quarter of growth. GSK beat earnings estimates as specialty medicine sales powered growth. —bit.ly/3JeBlY5

Tue news: Novartis faces $1.9B hit from Avidity fail. US biotechs take lion’s share of $54.5B VC money raised since 2025. Abbott launches next-gen ultra-sensitive residual disease test for cancer. GSK expects to nearly double cancer drug pipeline in 2027. —bit.ly/3JeBlY5

Mon news: Amgen-AZ lung cancer combo cuts risk of death by 58%. Roche's experimental lung cancer drug beat two rivals in a pivotal trial. Edwards wins FDA approval for tricuspid valve repair device. Bayer gets first approval for stroke drug asundexian. —bit.ly/3JeBlY5

Fri news: BMS discloses patient death in cell therapy study. Novartis' breast cancer drug cuts risk of death by 19% after 6 years. Takeda preps filings on gastric cancer data. After leak, Merck and Moderna post phase 3 cancer vaccine data early. —bit.ly/3JeBlY5

Boards are backing open for posting this afternoon!

IMPORTANT: Our boards are currently set to read only while we work on mitigating the security risk that was recently discovered and is affecting a large portion of sites globally. We will have the boards back on for posting as soon as possible. Thank you for your patience.

Thurs news: Roche's Q3 results top expectations. Labcorp to buy Myriad’s prenatal health testing unit for $210M. ICER says most new drugs still too costly to launch. AAZ grabs FDA nod for Ultomiris in rare kidney disease IgAN. —bit.ly/3JeBlY5

Tue news: Novo’s next-gen obesity drug shows 25% weight loss in women. GSK’s Jemperli scores FDA approval in rectal cancer. Amgen-AZ’s Tezspire win in EoE. AZ and Oracle team up on AI platform for clinical trials. —bit.ly/3JeBlY5

Mon news: Roche in $15B biobucks pact with China ADC powerhouse. Merck KGaA buys Silence in $1.3B deal after siRNA drug's ph 2 blood cancer win. Gilead hits mid-stage trial success for oral UC therapy. Novartis abandons Fabhalta trial in lupus nephritis. —bit.ly/3JeBlY5

Fri news: Lilly’s Foundayo wins Europe regulatory panel backing. RNAi biotech City hauls in $200m in upsized IPO. Edwards’ Sapien M3 delivery system linked to patient death. FDA clears Roche's Enspryng for thyroid eye disease. —bit.ly/3JeBlY5

Thurs news: AI paying Insitro $40M for AI drug discovery. Iambic’s $150M IPO to accelerate clinical development of oncology pipeline. Roche breast cancer drug Itovebi turned down by NICE. Ultragenyx sells priority review vouchers for $413M. —bit.ly/3JeBlY5

Wed news: Zealand pens up to $1.2B deal with Generate for AI obesity/metabolic drugs. FDA accepts BLA for first Keytruda biosimilar. Galderma to acquire ZO Skin Health for $1.5B. GSK to cut 1200 jobs in Belgium. —bit.ly/3JeBlY5

Tues news: Roche expands obesity R&D footprint with Rona deal worth $1B+. Pfizer pens $500M Enodia pact to join emerging protein degrader field. Bausch + Lomb names Appio interim CEO as Saunders hits the exit again. JNJ raises full year profit forecast. —bit.ly/3JeBlY5

Thurs news: Viatris to snap up Pacira's non-opioid pain pipeline for $1.65B. Q3 layoffs down YOY, affecting 90% fewer biopharma employees. 5 key facts about the FDA expedited IND pilot program. Pfizer's Tukysa greenlit for earlier use in breast cancer. —bit.ly/3JeBlY5

New on CP Wire:  ezCater's new ebook, Fueling Pharma and Biotech Innovation, makes the case that one of the most effective retention and collaboration tools is also one of the simplest: feeding people. @ezCater cafepharma.com/cpwire/articl…

Wed news: Court orders Merck to halt sale of Keytruda SC in multiple EU countries. Infinitus launches AI agents to help pharma teams reach more providers. Bayer commits $2.2B to build pharma manufacturing plant in Ohio. Stryker CEO Kevin Lobo to resign. —bit.ly/3JeBlY5